Business Wire

Affinity and Dealroom.co Partner to Bring Global Relationship and Predictive Intelligence to Dealmakers

Share

Affinity, the relationship intelligence platform for dealmakers, and Dealroom.co, a global provider of data and intelligence on startups and tech ecosystems, today announced a partnership to provide the most powerful combination of predictive intelligence and relationship intelligence for dealmakers. The partnership will provide Affinity clients with additional data intelligence for over 1.7 million startups and 2.1 million organizations globally. Joint clients of both Affinity and Dealroom.co will be able to access even more insights through additional data columns.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005042/en/

“Our clients use Affinity to find, manage, and close the most important deals, and using organizational data insights helps them to target the right organizations is a critical part of their success,“ said Ray Zhou, CEO of Affinity. “Adding Dealroom.co’s predictive intelligence data to Affinity will ensure they can do that faster and with more confidence than ever before. ”

Affinity’s platform will integrate Dealroom.co’s wide range of critical data to enrich organizational records with additional firmographic data, predictive data insights, and leading market momentum indicators (such as social engagement). This will enable investors, M&A professionals, and other dealmakers to deliver the most complete understanding of deal opportunities and reduce the time they spend deciding which deals or organizations to focus on. Joint clients of both organizations will also receive access to additional Dealroom.co data columns in Affinity, including app downloads, website traffic, and founders’ history of success, further streamlining organizational intelligence gathering.

“As the intelligence layer for tech ecosystems, we help clients discover the world’s most promising companies through predictive intelligence,” said Yoram Wijngaarde, Founder and CEO at Dealroom.co. “This partnership puts this timely data into the hands of more investors around the world. We're excited to work with Affinity to provide investors with the data they need to be successful.”

Learn more about the power of Affinity and Dealroom.co’s data in the recently released joint report “Relationship Intelligence Benchmark Report: European Unicorn Edition,” and watch the “European Unicorn Trends: How to Make Unicorn Hunting More Predictable” webinar which brings industry experts together to discuss the trends impacting dealmakers as well as the role relationship intelligence plays in the evolving market landscape.

Across the Affinity platform, over 500,000 new introductions are made and 450,000 deals are managed per month, helping dealmakers to find, manage, and close more deals. Currently, Affinity serves over 2,000 clients worldwide, including 500 in Europe where many already use Dealroom.co data in their dealmaking process. By capturing the exhaust of relationship interactions—over 18 trillion emails and 213 million calendar invites to date—Affinity automates the creation of contact and company records and tracks activity saving over 220 hours every year in data entry work.

About Affinity

Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations around the world. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.

About Dealroom.co

Dealroom.co is the foremost data provider on startups, innovation, high-growth companies,

ecosystems, and emerging tech. Founded in Amsterdam in 2013, Dealroom.co works with many of the world’s most prominent investors, entrepreneurs, and government organizations to provide transparency, analysis, and insights on venture capital activity. Dealroom.co mission is to accelerate entrepreneurship and innovation through data, insights, and predictive intelligence.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bospar
Sana Javaid
PRforAffinity@bospar.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom